Table 1

Clinical characteristics of MS patients and controls
Patient no. Age* (years) Sex* Duration of MS (years) Clinical subtype Current DMT EDSS Control no. Age (years) Sex
1 23 m 4 RRMS (FTY/Plac) 2.0 1 26 m
2 23 m 7 RRMS FING 2.0 2 27 m
3 32 m 9 RRMS IF 1,0 3 27 m
4 32 m 6 RRMS GA 0.0 4 33 m
5 34 m 4 RRMS NAT 3.5 5 35 m
6 48 m 3 RRMS IF 2.0 6 45 m
7 23 f 6 RRMS NAT 1.5 7 24 f
8 25 f 6 RRMS IF 1.5 8 26 f
9 25 f 8 RRMS IF 1.5 9 26 f
10 28 f 7 RRMS IF 2.0 10 26 f
11 29 f 1 RRMS IF 1.0 11 26 f
12 31 f 3 RRMS IF 1.0 12 28 f
13 33 f 9 RRMS IF 2.5 13 33 f
14 36 f 9 RRMS IF 1.5 14 45 f
Mean 30.1 5.9 Median 1.5 Mean ± 30.5
± SD ± 6.8 ± 2.5 [range] [0–3.5] SD ± 6.9

*Patients listed by gender and age.

m = male; f = female; EDSS = expanded disability status scale; RRMS = Relapsing-Remitting MS; SPMS = Secondary Progressive MS; DMT = disease modifying therapy with immunomodulators; FING = fingolimod; GA = glatiramer acetate; IF = interferon beta; MIT = mitoxantrone; NAT = natalizumab; (FTY/Plac) = fingolimod or placebo; patient participated in a randomized controlled treatment trial with undisclosed allocation.

Zeller et al.

Zeller et al. BMC Neurology 2012 12:92   doi:10.1186/1471-2377-12-92

Open Data